Skip to main content
. 2026 Nov 14;30(12):577. doi: 10.1007/s00784-026-07278-9

Table 2.

Treatment characteristics of the study participants (n = 56)

Treatment characteristic n (%)
Treatment modality
  Systemic antineoplastic therapy 26 (46.4)
  HSCT conditioning 24 (42.9)
  Concurrent head and neck chemoradiotherapy 5 (8.9)
  Head and neck radiotherapy alone 1 (1.8)
HSCT characteristics (n = 24)
  Autologous HSCT 17 (70.8)
  Allogeneic HSCT 7 (29.2)
  Myeloablative conditioning 20 (83.3)
  Reduced-intensity conditioning 4 (16.7)
  TBI 1 (4.2)
Conditioning regimen (n = 24)
  Melphalan-based, without other conditioning agents 10 (41.7)
  Busulfan + fludarabine ± ATG 7 (29.2)
  Busulfan + melphalan 5 (20.8)
  BEAM 1 (4.2)
  Cyclophosphamide + busulfan 1 (4.2)
Systemic antineoplastic therapy (n = 26)
  Treatment regimen/phase documented 26 (100.0)
Days from last systemic treatment to retained assessmentMedian (IQR) 10.5(5.25–13.5)
   Range, days 1–75
Head and neck radiotherapy (n = 6)
  Concurrent systemic therapy 5 (83.3)
  Radiotherapy alone 1 (16.7)
  35 prescribed fractions 5 (83.3)
  29 prescribed fractions 1 (16.7)
Cumulative RT dose at retained assessment (n = 6)
 20 Gy 1 (16.7)
  24 Gy 1 (16.7)
  33.75 Gy 1 (16.7)
  70 Gy 3 (50.0)

Percentages within HSCT and radiotherapy sections use their respective subgroup denominators. ATG antithymocyte globulin; BEAM, carmustine, etoposide, cytarabine, and melphalan, HSCT hematopoietic stem cell transplantation, IQR interquartile range, RT radiotherapy, TBI total-body irradiation